Biodegradable Microspheres and Hydrogel Drug Delivery System of Tumor Necrosis Factor (TNF) Inhibitor and Growth Differentiation Factor 5 (GDF5) Reduces Disc Inflammation in the Rabbit Model

Bo Yuan,Kayla Rudeen,Jun Li,Brandon Williams,Saurav Sumughan,Gregory Lopez,Howard S. An,Jennifer J. Kang-Mieler,Ana V. Chee
DOI: https://doi.org/10.1097/brs.0000000000004686
IF: 3.241
2023-04-17
Spine
Abstract:STUDY DESIGN: Preclinical study.OBJECTIVE: Develop and test a drug delivery system (DDS) composed of anti-inflammatories and growth factors in the rabbit disc injury model.SUMMARY OF BACKGROUND DATA: Biological therapies that inhibit inflammation or enhance cell proliferation can alter intervertebral disc (IVD) homeostasis to favor regeneration. Since biological molecules have short half-lives and one molecule may not cover multiple disease pathways, effective treatments may require a combination of growth factors and anti-inflammatory agents delivered in a sustained manner.METHODS: Biodegradable microspheres were generated separately to encapsulate tumor necrosis factor alpha (TNFα) inhibitors [etanercept (ETN)] or growth differentiation factor 5 (GDF5) and were embedded into a thermo-responsive hydrogel. Release kinetics and activity of ETN and GDF5 were measured in vitro. For in vivo testing, New Zealand White rabbits (n=12) underwent surgery for disc puncture and treatment with blank-DDS, ETN-DDS, or ETN+GDF5-DDS at levels L34, L45, and L56. Radiographic and magnetic resonance images of the spines were obtained. The IVDs were isolated for histological and gene expression analyses.RESULTS: ETN and GDF5 were encapsulated into PLGA microspheres and had average initial bursts of 2.4±0.1 μg and 11.2±0.7 μg from DDS, respectively. In vitro studies confirmed that ETN-DDS inhibited TNFα-induced cytokine release and GDF5-DDS induced protein phosphorylation. In vivo studies showed that rabbit IVDs treated with ETN+GDF5-DDS had better histological outcomes, higher levels of extracellular, and lower levels of inflammatory gene expression than IVDs treated with blank- or ETN-DDS.CONCLUSION: This pilot study demonstrated that DDS can be fabricated to deliver sustained and therapeutic dosages of ETN and GDF5. In addition, ETN+GDF5-DDS may have greater anti-inflammatory and regenerative effects than ETN-DDS alone. Thus, intradiscal injection of controlled release TNF-α inhibitors and growth factors may be a promising treatment to reduce disc inflammation and back pain.
clinical neurology,orthopedics
What problem does this paper attempt to address?